Alphamab Oncology has announced that JSKN003, a drug co-developed with Shanghai JMT-Bio Technology Co., Ltd., a subsidiary of CSPC Pharmaceutical Group Limited, has been granted breakthrough therapy designation by the Center for Drug Evaluation $(CDE)$ of China's National Medical Products Administration. The designation is for the treatment of HER2-positive advanced colorectal cancer in patients who have failed prior treatments with oxaliplatin, fluorouracil, and irinotecan. This follows a previous breakthrough therapy designation in March 2025 for JSKN003 in the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.